Key Players in the Peptide Therapeutics CDMO Market: Company Profiles

By /

Peptide Therapeutics CDMO Market Companies

Peptide Therapeutics CDMO Market Companies
  • Almac Group
  • AmbioPharm Inc.
  • American Peptide Company
  • Auspep Pty Ltd.
  • Bachem AG
  • BCN Peptides S.A.
  • Chinese Peptide Company (CPC)
  • CordenPharma International
  • CPC Scientific Inc.
  • Creative Peptides
  • CSBio Co.
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Peptide Institute Inc.
  • Piramal Pharma Solutions
  • PolyPeptide Group
  • Sanofi (Zentiva)
  • ScinoPharm Taiwan Ltd.
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.

Get Sample Report

1. Almac Group

  • Company Name and Headquarters: Almac Group (Craigavon, UK)

  • Product Offerings: Comprehensive services spanning drug discovery, development, manufacturing (API and drug product), and clinical trial supply. Their peptide capabilities include custom peptide synthesis, GMP manufacturing of clinical and commercial peptides, and advanced analytical services.

  • Market Share and Estimated Revenue: Almac is a significant player with a strong presence in high-potency API and complex molecule manufacturing, including peptides. Specific revenue figures for their peptide CDMO segment are not publicly disclosed but are estimated to be substantial given their integrated offerings.

  • Recent Developments, Partnerships, or Innovations: Continuously invests in expanding manufacturing capacity and analytical technologies for complex APIs, including peptides and oligonucleotides. Focus on green chemistry and sustainable manufacturing processes.

  • Competitive Positioning and Strategic Focus: Positions itself as a premium, integrated CDMO offering end-to-end solutions. Strategic focus on high-value, complex molecules, and personalized medicine, leveraging its expertise across the drug development lifecycle.

  • Key Customers or Industries Served: Global pharmaceutical and biotech companies, from virtual startups to large established firms, involved in various therapeutic areas.

2. AmbioPharm Inc.

  • Company Name and Headquarters: AmbioPharm Inc. (North Augusta, SC, USA)

  • Product Offerings: Specializes exclusively in peptide synthesis and manufacturing. Offers custom peptide synthesis (research to GMP), large-scale cGMP peptide manufacturing, peptide drug substance manufacturing, and process development.

  • Market Share and Estimated Revenue: One of the leading pure-play peptide CDMOs globally. While specific revenue figures are not public, they are recognized as a major contributor to the market.

  • Recent Developments, Partnerships, or Innovations: Continuous expansion of manufacturing capacity to meet growing demand for therapeutic peptides. Focus on efficient large-scale production.

  • Competitive Positioning and Strategic Focus: Strategic focus on being a dedicated, high-quality, and cost-effective peptide CDMO. Leverages its specialized expertise to offer competitive pricing and fast turnaround times, particularly for large-scale projects.

  • Key Customers or Industries Served: Pharmaceutical companies, biotech firms, and academic institutions developing peptide-based therapeutics.

3. American Peptide Company (owned by Bachem AG)

  • Company Name and Headquarters: American Peptide Company (Sunnyvale, CA, USA) – Now a subsidiary of Bachem AG.

  • Product Offerings: Prior to acquisition, offered a wide range of custom peptides, catalog peptides, and cGMP manufacturing services. Now integrated into Bachem’s global offerings, contributing to Bachem’s comprehensive peptide synthesis and manufacturing capabilities in North America.

  • Market Share and Estimated Revenue: Its contribution is now part of Bachem’s overall market share and revenue.

  • Recent Developments, Partnerships, or Innovations: The acquisition by Bachem AG in 2007 was a significant development, strengthening Bachem’s global presence.

  • Competitive Positioning and Strategic Focus: As part of Bachem, it supports Bachem’s strategy of being a global leader in peptide and oligonucleotide manufacturing.

  • Key Customers or Industries Served: Pharmaceutical and biotech companies.

4. Auspep Pty Ltd.

  • Company Name and Headquarters: Auspep Pty Ltd. (Parkville, Victoria, Australia)

  • Product Offerings: Focuses on custom peptide synthesis for research and early-stage drug discovery. Offers a wide range of modifications, peptide libraries, and complex peptide synthesis. While not a large-scale cGMP manufacturer for commercial therapeutics, they support preclinical development.

  • Market Share and Estimated Revenue: A smaller, specialized player in the research and preclinical peptide synthesis market. Specific revenue figures are not public.

  • Recent Developments, Partnerships, or Innovations: Continues to innovate in complex peptide synthesis methodologies.

  • Competitive Positioning and Strategic Focus: Niche focus on high-quality, complex research peptides and early-stage development support, particularly for academic and smaller biotech clients.

  • Key Customers or Industries Served: Academic research institutions, biotech startups, and pharmaceutical companies requiring bespoke peptides for discovery and preclinical studies.

5. Bachem AG

  • Company Name and Headquarters: Bachem AG (Bubendorf, Switzerland)

  • Product Offerings: A global leader in the development and manufacturing of peptides and oligonucleotides. Offers a vast catalog of research-grade peptides, custom peptide synthesis (research to cGMP), process development, and large-scale cGMP manufacturing for clinical and commercial supply.

  • Market Share and Estimated Revenue: Bachem is one of the largest and most established players in the peptide CDMO market, holding a significant share. Their annual revenue (total company) is in the hundreds of millions of Swiss Francs, with a substantial portion attributed to their CDMO peptide business.

  • Recent Developments, Partnerships, or Innovations: Continuous investment in expanding production capacity, particularly for large-scale cGMP manufacturing. Strong focus on sustainability and advanced manufacturing technologies. Recent expansions in their Swiss and US facilities.

  • Competitive Positioning and Strategic Focus: Positions itself as a premium, high-quality provider with extensive expertise and robust regulatory compliance. Strategic focus on being a full-service partner for peptides and oligonucleotides, from early research to commercial supply.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms of all sizes, and research institutions.

6. BCN Peptides S.A.

  • Company Name and Headquarters: BCN Peptides S.A. (Barcelona, Spain)

  • Product Offerings: Specializes in the cGMP manufacturing of therapeutic peptides. Offers process development, scale-up, and manufacturing of peptide APIs for clinical and commercial use.

  • Market Share and Estimated Revenue: A reputable mid-sized player in the European peptide CDMO market. Specific revenue figures for their peptide CDMO segment are not publicly disclosed.

  • Recent Developments, Partnerships, or Innovations: Focus on expanding cGMP manufacturing capabilities and maintaining high-quality standards.

  • Competitive Positioning and Strategic Focus: Strategic focus on providing flexible and reliable cGMP peptide manufacturing services, particularly for European clients and those seeking a strong European base. Emphasis on quality and regulatory compliance.

  • Key Customers or Industries Served: Pharmaceutical companies and biotech firms, mainly in Europe but also serving global clients.

7. Chinese Peptide Company (CPC)

  • Company Name and Headquarters: Chinese Peptide Company (CPC) (Hangzhou, China)

  • Product Offerings: Offers a wide range of peptide products, including custom peptide synthesis, catalog peptides, and cGMP manufacturing of peptide APIs. Serves both research and pharmaceutical markets.

  • Market Share and Estimated Revenue: A significant player in the Asian market, and increasingly globally, particularly known for competitive pricing. Specific revenue figures are not widely publicized.

  • Recent Developments, Partnerships, or Innovations: Investing in expanding cGMP facilities and improving quality systems to meet international regulatory standards.

  • Competitive Positioning and Strategic Focus: Strategic focus on providing cost-effective peptide synthesis and manufacturing services, leveraging its presence in China. Aims to compete globally on price and increasingly on quality.

  • Key Customers or Industries Served: Pharmaceutical companies, biotech firms, and research institutions worldwide, with a strong presence in Asia.

8. CordenPharma International

  • Company Name and Headquarters: CordenPharma International (Luxembourg)

  • Product Offerings: A full-service CDMO with extensive capabilities, including highly potent APIs, lipids, and peptides. Their peptide offerings include custom peptide synthesis, process development, cGMP manufacturing of peptide APIs (from clinical to commercial scale), and oligonucleotide synthesis.

  • Market Share and Estimated Revenue: A major global CDMO with significant revenue. While not solely focused on peptides, their peptide segment is a substantial part of their overall business.

  • Recent Developments, Partnerships, or Innovations: Continuous investment in expanding manufacturing capabilities across various modalities, including peptides. Focus on integrated supply chains and specialized technologies (e.g., highly potent peptides).

  • Competitive Positioning and Strategic Focus: Positions itself as a specialty CDMO focusing on complex molecules and integrated supply solutions. Strategic focus on high-value products and strong customer partnerships, offering both small- and large-molecule capabilities.

  • Key Customers or Industries Served: Global pharmaceutical and biotech companies, especially those with complex API needs or requiring integrated drug substance/drug product manufacturing.

9. CPC Scientific Inc.

  • Company Name and Headquarters: CPC Scientific Inc. (Sunnyvale, CA, USA)

  • Product Offerings: Specializes in custom peptide synthesis, catalog peptides, and cGMP manufacturing of peptide APIs. Offers services from research-grade to commercial-scale production.

  • Market Share and Estimated Revenue: A well-regarded mid-sized player, particularly strong in the US market. Specific revenue figures for their peptide CDMO segment are not publicly available.

  • Recent Developments, Partnerships, or Innovations: Focus on expanding cGMP manufacturing capacity and maintaining strong quality systems.

  • Competitive Positioning and Strategic Focus: Strategic focus on providing high-quality, reliable peptide synthesis and manufacturing services, with a strong emphasis on customer service and scientific expertise.

  • Key Customers or Industries Served: Biotech and pharmaceutical companies, as well as academic research institutions, primarily in North America but also serving international clients.

10. Creative Peptides

  • Company Name and Headquarters: Creative Peptides (Shirley, NY, USA)

  • Product Offerings: Primarily focused on research-grade peptides, custom peptide synthesis for discovery, and catalog peptides. While they offer high-purity peptides, their main focus is often on the early-stage development and research market rather than large-scale cGMP commercial production. They also offer some peptide modification services.

  • Market Share and Estimated Revenue: A smaller player in the research and preclinical peptide synthesis space. Specific revenue figures are not public.

  • Recent Developments, Partnerships, or Innovations: Continuous efforts to expand their catalog and custom synthesis capabilities for diverse research needs.

  • Competitive Positioning and Strategic Focus: Focuses on providing a wide range of custom peptides for research and early development, emphasizing flexibility and scientific support.

  • Key Customers or Industries Served: Academic researchers, biotech startups, and pharmaceutical companies requiring peptides for R&D.

11. CSBio Co.

  • Company Name and Headquarters: CSBio Co. (Menlo Park, CA, USA)

  • Product Offerings: Offers automated peptide synthesizers, reagents, and cGMP peptide manufacturing services. Their CDMO services include custom peptide synthesis (research to cGMP), process development, and large-scale manufacturing of peptide APIs.

  • Market Share and Estimated Revenue: A significant player with a unique offering of both equipment and CDMO services. Specific revenue figures for their CDMO segment are not publicly available.

  • Recent Developments, Partnerships, or Innovations: Continued development of advanced peptide synthesis automation and expansion of their manufacturing capabilities.

  • Competitive Positioning and Strategic Focus: Unique positioning as a provider of both peptide synthesis equipment and high-quality CDMO services. Strategic focus on leveraging their expertise in synthesis technology to deliver efficient and reliable peptide manufacturing.

  • Key Customers or Industries Served: Pharmaceutical companies, biotech firms, and academic institutions, particularly those looking for integrated solutions or seeking to outsource peptide manufacturing.

12. GenScript Biotech Corporation

  • Company Name and Headquarters: GenScript Biotech Corporation (Nanjing, China, with significant global operations including US headquarters in Piscataway, NJ)

  • Product Offerings: A broad life science service provider. Their peptide offerings include custom peptide synthesis (research to cGMP), peptide libraries, peptide array services, and antibody production against peptides. While offering cGMP, they are also very strong in the research and discovery phase.

  • Market Share and Estimated Revenue: A very large and diversified life science company. While not purely a peptide CDMO, their peptide synthesis revenue is substantial due to their extensive client base in research and early development.

  • Recent Developments, Partnerships, or Innovations: Continuous expansion of service offerings across gene synthesis, protein expression, and peptide synthesis. Investing in automation and high-throughput technologies.

  • Competitive Positioning and Strategic Focus: Positions itself as an integrated life science CRO/CDMO, offering a wide range of services. Strategic focus on being a “one-stop shop” for biological research and development, leveraging their strong R&D capabilities and global reach.

  • Key Customers or Industries Served: Global academic research institutions, biotechnology companies, and pharmaceutical companies across various R&D stages.

13. Lonza Group Ltd.

  • Company Name and Headquarters: Lonza Group Ltd. (Basel, Switzerland)

  • Product Offerings: A leading global CDMO with a vast portfolio including mammalian, microbial, cell and gene therapy, and small molecules. Their peptide capabilities include process development and cGMP manufacturing of peptide APIs, often integrated into broader drug substance or drug product projects. They are particularly strong in complex and larger peptide sequences and often serve as a partner for late-stage clinical and commercial supply.

  • Market Share and Estimated Revenue: Lonza is one of the largest CDMOs globally, with total revenues in the billions of CHF. While specific peptide CDMO revenue is not disclosed, it forms a significant component of their small molecules and specialized API offerings.

  • Recent Developments, Partnerships, or Innovations: Continuous investment in expanding manufacturing capacity and technological platforms across all modalities, including advanced analytics for complex molecules like peptides.

  • Competitive Positioning and Strategic Focus: Positions itself as a premier, integrated, and science-driven CDMO. Strategic focus on high-value, complex biopharmaceuticals and small molecules, offering end-to-end solutions and strong regulatory expertise.

  • Key Customers or Industries Served: Global pharmaceutical and biotech companies, ranging from large pharma to emerging biotechs, across all therapeutic areas.

14. Peptide Institute Inc. (owned by Bachem AG)

  • Company Name and Headquarters: Peptide Institute Inc. (Osaka, Japan) – Now a subsidiary of Bachem AG.

  • Product Offerings: Prior to acquisition, was a well-respected provider of research reagents, custom peptide synthesis, and some cGMP manufacturing. Now integrated into Bachem’s global operations, strengthening Bachem’s presence and capabilities in Asia.

  • Market Share and Estimated Revenue: Its contribution is now part of Bachem’s overall market share and revenue.

  • Recent Developments, Partnerships, or Innovations: Acquisition by Bachem AG in 2011 was a key event, expanding Bachem’s global footprint.

  • Competitive Positioning and Strategic Focus: As part of Bachem, it supports Bachem’s strategy of being a global leader in peptide and oligonucleotide manufacturing, particularly enhancing their reach in the Asian market.

  • Key Customers or Industries Served: Pharmaceutical, biotech, and research institutions.

15. Piramal Pharma Solutions

  • Company Name and Headquarters: Piramal Pharma Solutions (Mumbai, India)

  • Product Offerings: A global CDMO offering a wide range of services, including API manufacturing (small molecules, HPAPIs), drug product, and sterile fill-finish. Their peptide capabilities include process development and cGMP manufacturing of peptide APIs, often as part of a broader integrated project for clients.

  • Market Share and Estimated Revenue: A significant global CDMO with substantial revenue. While peptides are a part of their overall API manufacturing, specific segment revenue is not disclosed.

  • Recent Developments, Partnerships, or Innovations: Expanding global manufacturing footprint and investing in specialized capabilities, including complex molecule synthesis.

  • Competitive Positioning and Strategic Focus: Positions itself as a reliable, high-quality, and flexible partner for integrated drug development and manufacturing. Strategic focus on offering a comprehensive suite of services and building long-term customer relationships.

  • Key Customers or Industries Served: Global pharmaceutical and biotech companies, particularly those seeking integrated solutions from development to commercialization.

16. PolyPeptide Group

  • Company Name and Headquarters: PolyPeptide Group (Malmö, Sweden, with global operations)

  • Product Offerings: One of the largest and most established pure-play peptide CDMOs. Offers comprehensive services from custom peptide synthesis (research to cGMP), process development, scale-up, and large-scale cGMP manufacturing of peptide APIs for clinical and commercial applications. Also provides oligonucleotide services.

  • Market Share and Estimated Revenue: A top-tier global leader in the peptide CDMO market, with significant market share and annual revenues in the hundreds of millions of Euros.

  • Recent Developments, Partnerships, or Innovations: Continuous investment in expanding global manufacturing capacity and technological capabilities. Strong focus on sustainability and operational excellence. Recently went public, indicating strong growth and market confidence.

  • Competitive Positioning and Strategic Focus: Positions itself as a dedicated, global, and highly reliable partner for therapeutic peptides and oligonucleotides. Strategic focus on high-quality, complex peptides, strong regulatory compliance, and a broad geographic footprint.

  • Key Customers or Industries Served: Global pharmaceutical and biotech companies, from virtual startups to large multinational corporations, developing a wide range of peptide therapeutics.

17. Sanofi (Zentiva) – Note on Zentiva:

  • Company Name and Headquarters: Zentiva (Prague, Czech Republic) was previously a part of Sanofi. Sanofi divested Zentiva in 2018. Zentiva now operates as an independent generics and OTC company.

  • Product Offerings (Zentiva): As an independent company, Zentiva primarily focuses on the development, manufacturing, and commercialization of branded and unbranded generic medicines and OTC products. Their CDMO involvement is more geared towards generic APIs and finished dosage forms rather than specialized peptide therapeutics CDMO services.

  • Market Share and Estimated Revenue: Zentiva is a significant player in the European generics market. Revenue figures are for their generics business, not specialized peptide CDMO.

  • Recent Developments, Partnerships, or Innovations: Focus on expanding their generics portfolio and manufacturing footprint for established products.

  • Competitive Positioning and Strategic Focus: Strategic focus on being a leading provider of affordable, high-quality generic medicines in Europe and beyond. Not a direct competitor in the specialized peptide therapeutics CDMO market.

  • Key Customers or Industries Served: Healthcare providers, pharmacies, and patients in the generics and OTC markets.

  • Regarding Sanofi: Sanofi itself primarily focuses on pharmaceutical R&D and commercialization. While they produce peptide drugs, they typically outsource their peptide API manufacturing to specialized CDMOs rather than offering CDMO services themselves. Therefore, Sanofi is primarily a customer of peptide CDMOs, not a provider in this context.

18. ScinoPharm Taiwan Ltd.

  • Company Name and Headquarters: ScinoPharm Taiwan Ltd. (Tainan, Taiwan)

  • Product Offerings: Focuses on the development and manufacturing of APIs, particularly for complex small molecules and highly potent APIs (HPAPIs). While their primary strength is in traditional small molecules, they do have capabilities for specialized synthesis, which can include certain complex peptide-like structures or intermediates.

  • Market Share and Estimated Revenue: A reputable API manufacturer, particularly known in Asia. Specific revenue from peptide-related CDMO services is not a primary highlight and would be part of their broader complex API segment.

  • Recent Developments, Partnerships, or Innovations: Investing in expanding HPAPI manufacturing and continuous process technologies.

  • Competitive Positioning and Strategic Focus: Strategic focus on being a high-quality API supplier for complex molecules, with strong regulatory compliance and a growing presence in the global market.

  • Key Customers or Industries Served: Pharmaceutical companies globally, especially those seeking partners for complex API manufacturing.

19. Siegfried Holding AG

  • Company Name and Headquarters: Siegfried Holding AG (Zofingen, Switzerland)

  • Product Offerings: A global CDMO with integrated capabilities for both drug substances (API) and drug products. Their API offerings include complex small molecules and specialized chemistry, which encompasses certain peptide and oligonucleotide manufacturing. They offer process development and cGMP manufacturing for clinical and commercial supply.

  • Market Share and Estimated Revenue: A significant global CDMO with substantial revenue. Peptide-related services are part of their broader API manufacturing portfolio.

  • Recent Developments, Partnerships, or Innovations: Continuous investment in expanding manufacturing capabilities and technologies, particularly for complex APIs and sterile drug products. Strategic acquisitions to broaden their service portfolio.

  • Competitive Positioning and Strategic Focus: Positions itself as an integrated partner for both API and drug product manufacturing, emphasizing reliability, quality, and regulatory excellence. Strategic focus on high-value products and complex chemistry.

  • Key Customers or Industries Served: Global pharmaceutical and biotech companies, seeking integrated solutions for drug substance and drug product manufacturing.

20. Thermo Fisher Scientific Inc.

  • Company Name and Headquarters: Thermo Fisher Scientific Inc. (Waltham, MA, USA)

  • Product Offerings: A massive global life sciences company with a wide array of products and services, including analytical instruments, lab equipment, reagents, and CDMO services. Within their Pharma Services division (acquired Patheon), they offer comprehensive CDMO services for small molecules, biologics, and specialized APIs, including peptides. Their peptide capabilities encompass custom synthesis (research to cGMP), process development, and manufacturing.

  • Market Share and Estimated Revenue: Thermo Fisher is one of the largest life science companies in the world, with multi-billion dollar revenues. Their CDMO segment is substantial, and peptide manufacturing contributes to this, although specific peptide revenue is not broken out.

  • Recent Developments, Partnerships, or Innovations: Continuous strategic acquisitions (e.g., Patheon) and investments in expanding their global CDMO footprint and technological capabilities across all modalities. Focus on end-to-end solutions.

  • Competitive Positioning and Strategic Focus: Positions itself as a leading, integrated CDMO offering comprehensive services across the entire pharmaceutical value chain, backed by its extensive R&D and technology portfolio. Strategic focus on being a premier partner for global pharmaceutical and biotech clients, leveraging scale and breadth of services.

  • Key Customers or Industries Served: Global pharmaceutical and biotech companies, academic institutions, and government agencies, covering a vast range of therapeutic areas and research needs.

Contact Us

Related Posts

Scroll to Top